COO
Fiscal year ends October Quarters are offset from the calendar — Q1 is Nov–Jan

The Cooper Companies, Inc. is a global medical device company operating through two business segments: CooperVision and CooperSurgical. CooperVision develops, manufactures, and markets contact lenses, including single-use, two-week, and monthly replacement lenses in spherical, toric, and multifocal designs. The segment offers myopia management products, such as the MiSight 1 day lens, as well as orthokeratology and scleral lenses. CooperSurgical provides products and services for fertility and women's health, including medical devices for gynecology and obstetrics, in vitro fertilization support, cryopreservation, and cord blood and tissue storage. The company serves customers across the Americas, Europe, Middle East, Africa, and Asia Pacific. CooperSurgical was established in 1990.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Devices Homepage coopercos.com
Sector Healthcare IR page investor.coopercos.com/press-releases
Tags
contact lenses, myopia management, fertility, women's health, in vitro fertilization, cryopreservation, obstetrics, gynecology, cord blood storage, surgical products, CooperVision, CooperSurgical, Biofinity, Avaira Vitality, MyDay, clariti 1 day, Proclear, Biomedics, MiSight 1 day
Press page —

Metrics

Valuation  
Market cap $ 10.746B
Market cap (USD) $ 10.746B
P/E 19.36
PEG —
P/BV 1.29
P/S 2.54
P/OCF 10.40
P/FCF 15.85
Dividend yield 0.11%
Turnover / mcap —
Returns  
ROE 4.6%
ROI 3.5%
ROIC 4.2%
Profit margin 9.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -0.95%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 30.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score 15.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 4.092B 3.895B 3.593B 3.308B 2.923B 2.431B 2.653B 2.533B 2.139B 1.967B 1.797B 1.718B 1.588B 1.445B 1.331B 1.159B 1.08B 1.063B 950.641M 858.96M 806.617M 490.176M 411.79M 315.306M — —
Net profit 374.9M 392.3M 294.2M 385.8M 2.945B 238.4M 466.7M 139.9M 372.9M 273.917M 203.523M 269.856M 296.151M 248.339M 175.43M 112.803M 100.548M 65.476M -11.192M 66.234M 91.722M 92.825M 68.77M 48.875M 37.136M 28.968M
Free cash flow 433.7M 288.1M 215M 450.4M 524.2M 176.2M 421.1M 475.3M 466.4M 357.037M 147.947M 216.758M 237.798M 215.342M 232.616M 193.906M 129.222M -28.357M -49.641M 7.852M 66.75M 60.693M 45.684M 32.513M 8.862M 26.363M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 68.56 110.34 370 410.55 440.94 350 303 275.86 245.33 185.72 150 161.37 122.94 97.32 75.39 50.9 30.25 21.54 52.03 56.11 — — — — — —
Price performance 12m -0.38 -0.7 -0.1 -0.07 0.26 0.16 0.1 0.12 0.32 0.24 -0.07 0.31 0.26 0.29 0.48 0.68 0.4 -0.59 -0.07 — — — — — — —

Filed figures

Figure Oct 2016 Oct 2017 Oct 2018 Oct 2019 Oct 2020 Oct 2021 Oct 2022 Oct 2023 Oct 2024 Oct 2025
Balance sheet detail
Trade receivables (USD) 291M 317M 375M 435M 435M 515M 558M 610M 717M 829M
↳ YoY growth +3.0% +8.7% +18.4% +16.2% +0.0% +18.4% +8.2% +9.3% +17.6% +15.6%
↳ 5y CAGR +6.3% +6.2% +10.3% +9.5% +9.0% +12.1% +12.0% +10.2% +10.5% +13.7%
Borrowings, current (USD) 437M 23.4M 37.1M 564M 409M 82.9M 413M 44.4M 32.2M 47.1M
Borrowings, non-current (USD) 1.11B 1.15B 1.99B 1.26B 1.38B 1.4B 2.35B 2.52B 2.55B 2.46B
Lease liabilities (USD) — — — — 270M 269M 262M 258M 273M 281M
Cash and deposits (USD) 101M 88.8M 77.7M 89M 116M 95.9M 138M 121M 108M 111M
Intangible assets (USD) 441M 505M 1.52B 1.41B 1.29B 1.27B 1.89B 1.71B 1.79B 1.59B
Right-of-use assets (USD) — — — — 260M 257M 230M 242M 261M 271M
Net debt (borrowings + leases - cash) (USD) 1.44B 1.08B 1.95B 1.74B 1.95B 1.65B 2.88B 2.7B 2.75B 2.67B
Cash flow detail
Operating cash flow (USD) 510M 594M 669M 713M 487M 739M 692M 608M 709M 796M
Purchases of property, plant and equipment (USD) -153M -127M -194M -292M -310M -214M -242M -393M -421M -362M
Change in receivables (cash effect) (USD) 1.65M -25.1M -59.5M -55.6M 8.5M -75.5M -33.8M -60.2M -117M -120M
Change in inventories (cash effect) (USD) 12.2M -30.9M -5M -37.3M -62.3M -9.2M -40.4M -105M -59.3M -46M
Change in payables (cash effect) (USD) -10.5M 25M 2.9M 3.6M 23.2M -16M 49.9M 5.5M 9.3M 8M
Dividends paid (cash effect) (USD) -2.91M -2.9M -2.9M -3M -3M -3M -3M -3M 0.00 0.00
Share buybacks (cash effect) (USD) 0.00 -55M 0.00 -156M -47.8M -24.8M -78.5M 0.00 0.00 -290M
Interest paid (cash effect) (USD) -23.7M -31.3M -82.1M -75.3M -46.5M -28.4M -49.1M -118M -135M -115M
Income taxes paid (cash effect) (USD) -29.4M -15.6M -18.8M -39.2M -51.1M -63.2M -66.6M -67.8M -78.4M -100M
Share-based compensation (USD) 29.9M 37.2M 43.2M 35.1M 37.6M 43.8M 54.2M 62.1M 75.1M 70.5M
Operating cash flow before change in receivables (USD) 508M 619M 728M 769M 478M 814M 726M 668M 826M 916M
Free cash flow (OCF - PPE - intangibles) (USD) 357M 466M 475M 421M 176M 524M 450M 215M 288M 434M
Income detail
Research and development expense (USD) 65.4M 69.2M 84.8M 86.7M 93.3M 92.7M 110M 137M 155M 172M
↳ 5y CAGR +8.5% +6.0% +7.6% +5.5% +6.0% +7.2% +9.8% +10.1% +12.3% +13.0%
Total comprehensive income (USD) -23M 487M 89.3M 450M 214M 3.08B 260M 307M 424M 390M
Comprehensive income to owners (USD) -24M 487M 89.3M 450M 214M 3.08B — — — —
Provision for credit losses (USD) 2.56M 2.3M 8.2M -2.6M -6.2M -2.5M — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.9% 0.8% 2.4% 0.6% 1.4% 0.5% — — — —
Reported Dec 22, 2016 Dec 22, 2017 Dec 21, 2018 Dec 20, 2019 Dec 11, 2020 Dec 10, 2021 Dec 9, 2022 Dec 8, 2023 Dec 6, 2024 Dec 5, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Press Release Details

Events & Presentations

CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2026

Nov 5, 2026

PDF Version

**SAN RAMON, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) --**CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report fourth quarter and full year 2026 financial results on Thursday, December 3, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

The dial-in number for the call is 800-715-9871 and the conference ID is 1193290. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com

Oct 27, 2026

Download PDF 191.5 KB

Independent Director and Seasoned Healthcare Executive Walt Rosebrough

Elected Executive Chair; Search for CEO Underway

Provides Update on Board Refreshment, Including Planned Addition of Medical Device and Vision Veteran Shlomi Nachman

Reaffirms Full-Year Fiscal 2026 Guidance

SAN RAMON, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) (the “Company”), a leading medical device company, today announced leadership changes and planned Board refreshment aimed at strengthening operational execution, improving business performance, and enhancing long-term shareholder value.

Walter (Walt) M Rosebrough, Jr., an independent director of the Company’s Board of Directors (the “Board”) and a proven healthcare executive with decades of experience, has been elected Executive Chair of the Board. Albert (Al) White III is stepping down from his position as President and Chief Executive Officer, and as a member of the Board, effective immediately. Mr. Rosebrough will assume direct oversight of day-to-day operations at the Company until a permanent CEO is appointed. Mr. White will remain employed as a strategic advisor through April 1, 2027.

The search for a permanent CEO is underway and is supported by leading professional search firm Russell Reynolds. The search is being overseen by a CEO Search Committee of the Board, comprised of Lawrence Kurzius, Cynthia Lucchese, and Teresa Madden. As Chair, Mr. Rosebrough will work closely with the CEO Search Committee and the full Board throughout the process, drawing on decades of experience leading medical device companies.

“I joined CooperCompanies because I believe there is great opportunity in its future. The Company’s recent performance has not met our expectations, and the Board believes decisive action is needed to ensure the Company reaches its long-term potential,” said Mr. Rosebrough, Executive Chair. “I will be working closely with the Board and the management team on priorities that will strengthen the foundation for growth and value creation.”

Mr. Rosebrough continued, “The Board is appreciative of Al’s leadership and valuable contributions to CooperCompanies throughout his 20 years with the Company.”

Board Refreshment

The Company also announced planned changes to its Board of Directors. Shlomo (Shlomi) Nachman will join the Board as an independent director, effective December 8, 2026. Mr. Nachman is a former Johnson & Johnson executive with over 27 years of healthcare experience, where he led a portfolio of medical device businesses, including Vision. He has a proven track record driving growth, innovation, and business turnarounds.

Further, three current Board members, Barbara Carbone, Colleen Jay, and Robert Weiss, have announced their intention not to stand for reelection at the Company’s 2027 Annual Meeting of Shareholders. These Board changes are in addition to the appointment of two independent directors in January and July of 2026, which followed constructive engagement with shareholders.

With these changes, the Board will nominate seven directors for election at the Annual Meeting: Paul Keel, Lawrence Kurzius, Cynthia Lucchese, Teresa Madden, Shlomi Nachman, Maria Rivas, MD, and Walt Rosebrough. The Board believes this seven-member Board will promote more focused oversight, efficient decision-making, and accountability, while maintaining the right mix of expertise and experience to oversee the Company. The seven directors who will be nominated include three current or former public company CEOs, two former public company CFOs, one former Chief Medical Officer of a global pharmaceutical company, and one former leader of a global vision business. Four of the directors have extensive medical device experience.

“These changes reflect the Board’s commitment to ensuring we have the appropriate mix of experience and expertise to oversee CooperCompanies’ strategy and support its long-term success,” said Cynthia Lucchese, Chair of the Corporate Governance and Nominating Committee. “We are pleased to welcome Shlomi Nachman, whose extensive experience in vision care and medical technology will be invaluable to CooperCompanies.”

Mr. Rosebrough concluded, “Our updated Board composition best positions us to provide active oversight in pursuit of long-term value creation. Our priorities are clear: identify and onboard the right CEO to lead the Company into its next chapter of growth and take additional actions to strengthen our business in order to provide superior products for customers, rewarding work for our people, and superior returns for our shareholders.”

The Company reaffirms the fiscal year 2026 guidance provided on September 9, 2026.

Sep 23, 2026

The Vision Centre Brings Industry Leading Innovation to Accelerate Breakthroughs in Eye Care

SAN RAMON, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today reinforced its commitment to accelerate growth at CooperVision with the opening of its new global innovation hub, The Vision Centre, and the announcement of six major product advancements that have been accelerated to launch over the next several years:

  • The build-out of the world's first & only complete family of 1-day contact lenses for myopia control, built on the world's #1 toric design;

  • A novel premium 1-day silicone hydrogel (SiHy) technology;

  • A next-generation SiHy material in a high-performing monthly contact lens;

  • A differentiated entry 1-day SiHy innovation to drive new fits;

  • The most advanced 1-day SiHy toric multifocal contact lens;

  • A new toric 1-day contact lens experience for astigmatic patients.

Together, these innovations represent one of the most ambitious product pipelines in CooperVision's history, reflecting the Company's confidence in the future of contact lenses and its commitment to advancing vision care through ongoing investment in science, technology, and clinical research.

"As we look to the future, innovation remains one of our most important growth drivers," said Al White, President and Chief Executive Officer of CooperCompanies. "Today's announcement demonstrates our commitment to investing behind our strongest opportunities. By expanding our innovation capabilities and bringing together world-class talent and technology, we are strengthening CooperVision's ability to accelerate new product introductions, drive category-leading science, and deliver sustainable long-term growth."

The Vision Centre is a major investment in CooperVision's innovation ecosystem that reflects the Company’s commitment to deploying capital toward high-return growth opportunities and accelerating organic growth through innovation. Based in Southampton, England, the new facility brings together research and development, clinical expertise, pilot manufacturing, advanced technologies, and commercial capabilities to accelerate the development and commercialization of breakthrough solutions for patients and eye care professionals worldwide.

"Today marks a new era in CooperVision’s longstanding legacy," said Jerry Warner, President of CooperVision. "CooperVision continues to evolve as an innovative, technology-forward and consumer-connected vision care leader, and the strategy and pipeline we previewed today reflects our commitment to develop breakthrough solutions that address the evolving needs of eye care professionals and patients worldwide."

The Vision Centre will serve as a global center for research, clinical studies, product development, and new product introduction (NPI) programs. Investments in this facility support CooperVision’s robust innovation pipeline across key growth categories, building upon the Company’s legacy of bringing market-leading silicon hydrogel materials, toric and multifocal designs, and myopia control to over 40 million people worldwide. Designed to foster greater collaboration across the innovation lifecycle, the facility will enable faster translation of scientific insights into commercialized solutions, helping CooperVision bring new technologies and products to market more efficiently. The facility will also leverage advanced digital tools, data science, analytics, and emerging AI-enabled capabilities to enhance product development.

The opening comes as the Company continues to invest in CooperVision commercial execution, operational excellence, and innovation. The Company will continue to provide additional updates over the coming quarters and remains focused on identifying opportunities to enhance revenue growth, expand profitability, and increase shareholder value.

Prompts

The Cooper Companies, Inc. (ticker COO), listed in United States.

ETFs Holding The Cooper Companies, Inc.

ETF Weight in ETF Shares Market value As of
CCFE 3.11% 16,539 $ 1M Nov 18, 2026
KMID 2.96% 18,688 $ 1.352M Jul 31, 2026
BASV 2.27% 129,080 $ 9.256M Jun 30, 2026
EQTY 2.01% 396,156 $ 28.65M Jul 31, 2026
CVSM 1.88% 24,508 $ 1.772M Jul 31, 2026
TMFM 1.63% 27,662 $ 1.939M Aug 31, 2026
BSMC 1.16% 26,800 $ 1.922M Jun 30, 2026
PINK 1.05% 57,659 $ 3.501M Nov 17, 2026
TMED 0.65% 2,088 $ 149.73K Jun 30, 2026
FEMV 0.65% 480 $ 34.421K Jun 30, 2026
FBCV 0.45% 11,032 $ 797.834K Jul 31, 2026
FMDE 0.36% 366,611 $ 26.29M Jun 30, 2026
DFAT 0.33% 1,655,138 $ 102.933M Nov 12, 2026
SPIN 0.28% 2,040 $ 126.235K Nov 16, 2026
DFSV 0.27% 1,211,254 $ 75.328M Nov 12, 2026
APUE 0.15% 52,683 $ 3.693M Aug 31, 2026
CLSE short -0.12% -15,543 $ -1.089M Aug 31, 2026
AVMC 0.12% 10,876 $ 673.007K Nov 16, 2026
FTLS short -0.10% -40,774 $ 0.00 Nov 16, 2026
DFAS 0.07% 360,475 $ 22.418M Nov 12, 2026
CAPE 0.06% 2,131 $ 152.814K Jun 30, 2026
VFVA 0.05% 7,148 $ 501.003K Aug 31, 2026
IALT short -0.04% -54,271 $ -3.358M Nov 16, 2026
DFUV 0.04% 95,818 $ 5.959M Nov 12, 2026
DXUV 0.04% 38,168 $ 2.374M Nov 12, 2026
DFAC 0.03% 476,749 $ 29.649M Nov 12, 2026
XMAG 0.03% 914 $ 56.842K Nov 13, 2026
MSLC 0.03% 14,792 $ 1.037M Aug 31, 2026
ACVF 0.02% 456 $ 32.978K Jul 31, 2026
DCOR 0.02% 148,654 $ 9.245M Nov 12, 2026
AVSU 0.02% 1,635 $ 101.174K Nov 16, 2026
AVLC 0.02% 5,871 $ 363.297K Nov 16, 2026
JSTC 0.02% 961 $ 59.467K Nov 17, 2026
DFSU 0.02% 7,349 $ 457.034K Nov 12, 2026
DFAU 0.02% 36,695 $ 2.282M Nov 12, 2026
HCMT 0.02% 1,360 $ 98.355K Jul 31, 2026
VOXP 0.01% 12 $ 867.84 Jul 31, 2026
AVUS 0.01% 34,506 $ 2.135M Nov 16, 2026
GSPY 0.01% 624 $ 38.613K Nov 17, 2026
DFUS 0.01% 34,608 $ 2.152M Nov 12, 2026
EBI 0.00% 174 $ 12.196K Aug 31, 2026
CSHP 0.00% 276 $ 17.079K Nov 16, 2026
CORO 0.00% 123 $ 7,606.85 Nov 16, 2026